|
UGN-501 Clinical Trials
1 actively recruiting trial across 1 location
Pipeline
Phase 1: 1
Top Sponsors
- UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.1
Indications
- Urothelial Carcinoma in Situ1
- Urothelial Carcinoma of the Urinary Bladder1
- Non-Muscle Invasive Bladder Carcinoma1
- NMIBC1
- Urothelial Carcinoma Recurrent1
Queen Creek, Arizona1 trial
A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC
East Valley Urology Center of Arizona
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.